C
Cambrian BioPharma
Biotechnology company developing transformative medicines for aging-related diseases
About Cambrian BioPharma
Cambrian Bio is a pioneering startup in the healthcare sector, focusing on the development of innovative medicines aimed at extending the healthspan - the period of life spent in good health. The company operates at the intersection of biomedicine and data science, using a data-driven approach to create a pipeline of therapies that could potentially redefine healthcare in the 21st century.
The company's primary clients are patients in need of new classes of medicines. These medicines are designed to understand and target the biological drivers of aging, with the potential to treat and prevent some of today's deadliest diseases. By partnering with exceptional scientists, Cambrian Bio is able to bring a fresh perspective and innovative solutions to the healthcare market.
Cambrian Bio's business model is centered around the development and distribution of these transformative therapies. The company makes money by creating effective and safe therapies and making them widely available to patients. This is achieved through rigorous scientific research and a bold mission to extend healthspan.
In summary, Cambrian Bio is a forward-thinking biomedicine company, using data-driven approaches to develop therapies that aim to extend the period of life spent in good health. Their business model is centered around the creation and distribution of these therapies, with a focus on accessibility for patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 30
- Open positions
- 4
- Dealroom signal
- 74.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, Longevity, DT and LS, science-based
- Client focus
- B2B
- Investment activity
- 7 companies, latest Oct 2022
- Capital deployed
- $268M
- Preferred round
- SERIES B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Feb 2026 | $0 | — | Advanced Research Projects Agency for Health - ARPA-H | ↗ |
| LATE VCOther financing | Jun 2023 | $0 | — | FJ Labs · SV Pacific Ventures | — |
Growth signals
Latest recorded traffic for Cambrian BioPharma is 5.4K monthly website visits, up 45.9% over the last three months. Cambrian BioPharma's team grew 7.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vita TherapeuticsBaltimore, United StatesDedicated scientists striving to advance treatments in multiple indications in cell therapy platform
$160Mvaluation
Oviva TherapeuticsNew York City, United StatesA movement to improve women's experience of aging through biomedical research, development and advocacy
$46Mvaluation
ArcellxGaithersburg, United StatesIntelligent and adaptive cell therapies to treat the complexity of human disease
$6.3Bvaluation
Sensei BiotherapeuticsGaithersburg, United StatesAn innovator in the field of next-generation cancer immunotherapies
$258Mvaluation
Cambrian BioPharma in the New York City ecosystem
The Cambrian BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Advanced Research Projects Agency for Health - ARPA-H
Series A3 investors entered at this stage
Future Ventures
Apeiron Investment Group
Korify Capital
Series B and later5 investors entered at this stage
Anthos Capital
Moore Capital
SALT Fund
FJ Labs
SV Pacific Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cambrian BioPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cambrian BioPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








